首页> 外国专利> METHOD FOR DETERMINING PROGNOSIS OF BREAST CANCER PATIENT AFTER TREATMENT WITH SURGERY

METHOD FOR DETERMINING PROGNOSIS OF BREAST CANCER PATIENT AFTER TREATMENT WITH SURGERY

机译:手术治疗后判断乳腺癌患者预后的方法

摘要

PROBLEM TO BE SOLVED: To provide a method and a kit for determining a prognosis of a breast cancer patient after treatment with surgery using biomarkers which can accurately determine a prognosis of a breast cancer patient after treatment with surgery.SOLUTION: A determination of a prognosis of a breast cancer patient after a treatment with surgery can be accurately made by using ten biomarker proteins (GP2_HUMAN, MFAP4_HUMAN, COEA1_HUMAN, TRYB1_HUMAN, ABCA8_HUMAN, CBG_HUMAN, KERA_HUMAN, OMD_HUMAN, PI15_HUMAN, and PTX3_HUMAN), and phosphorylation of amino acid residues such as amino acid residues in four biomarker phosphorylated proteins (the 352nd serine residue of CCR1_HUMAN, the 1208th threonine residue of PDS5A_HUMAN, the 417th serine residue of LMO7_HUMAN, the 417th serine residue of LMO7_HUMAN, and the 13th serine residue of ALG3_HUMAN), as biomarkers.
机译:要解决的问题:提供一种使用生物标记物确定手术治疗后的乳腺癌患者预后的方法和试剂盒,可以准确地确定手术治疗后的乳腺癌患者的预后。解决方案:预后的确定可以通过使用十种生物标记蛋白(GP2_HUMAN,MFAP4_HUMAN,COEA1_HUMAN,TRYB1_HUMAN,ABCA8_HUMAN,CBG_HUMAN,KERA_HUMAN,OMD_HUMAN,PI15_HUMAN和PTX3_HUMAN的十个生物标记蛋白和残基的磷酸化来准确地对乳腺癌患者进行手术治疗)四个生物标记磷酸化蛋白的氨基酸残基(CCR1_HUMAN的第352个丝氨酸残基,PDS5A_HUMAN的第1208个苏氨酸残基,LMO7_HUMAN的第417个丝氨酸残基,LMO7_HUMAN的第417个丝氨酸残基和ALG3_HUMAN的第13个丝氨酸残基)。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号